Heron Therapeutics (HRTX) Equity Ratio (2016 - 2025)
Heron Therapeutics' Equity Ratio history spans 14 years, with the latest figure at 0.06 for Q4 2025.
- For Q4 2025, Equity Ratio rose 138.81% year-over-year to 0.06; the TTM value through Dec 2025 reached 0.06, up 138.81%, while the annual FY2025 figure was 0.06, 138.81% up from the prior year.
- Equity Ratio reached 0.06 in Q4 2025 per HRTX's latest filing, down from 0.06 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.63 in Q1 2021 to a low of 0.2 in Q2 2023.
- Average Equity Ratio over 5 years is 0.02, with a median of 0.07 recorded in 2022.
- Peak YoY movement for Equity Ratio: crashed 382.32% in 2023, then skyrocketed 138.81% in 2025.
- A 5-year view of Equity Ratio shows it stood at 0.25 in 2021, then crashed by 78.69% to 0.05 in 2022, then plummeted by 382.32% to 0.15 in 2023, then rose by 5.47% to 0.14 in 2024, then skyrocketed by 138.81% to 0.06 in 2025.
- Per Business Quant, the three most recent readings for HRTX's Equity Ratio are 0.06 (Q4 2025), 0.06 (Q3 2025), and 0.12 (Q2 2025).